Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + ipilimumab versus EXTREME regimen in first-line recurrent or metastatic SCCHN
2016-000725-39Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Overall survival and Progression-free survival. Started Jul 2016; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2016-000725-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000725-39.